Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Percheron Therapeutics (AU:PER)
ASX:PER
RESEARCH TOOLSreports
Holding AU:PER?
Track your performance easily
PER Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.05 - AU$0.14
Previous CloseAU$0.07
Volume290.93K
Average Volume (3M)2.67M
Market Cap
AU$80.71M
Enterprise ValueAU$59.43M
Total Cash (Recent Filing)AU$19.23M
Total Debt (Recent Filing)AU$227.40K
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Feb 26, 2025EPS Estimate
-AU$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares OutstandingN/A
10 Day Avg. Volume2,723,642
30 Day Avg. Volume2,672,563
Standard Deviation0.20
R-Squared0.00744
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)112.18
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.25Price Target Upside248.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Percheron Therapeutics News
PremiumCompany Announcements
Percheron Therapeutics Announces New ASX Securities Quotation
PremiumCompany Announcements
Percheron Therapeutics’ Director Acquires New Options
PremiumCompany Announcements
Percheron Therapeutics Issues New Unquoted Options
PremiumCompany Announcements
Percheron Therapeutics to Issue 3 Million Options
PremiumCompany Announcements
Percheron Therapeutics Announces New Security Issuance
PremiumCompany Announcements
Percheron Therapeutics Faces First Strike Amidst New TrialsPremiumCompany Announcements
Percheron Therapeutics’ Promising Advances in Duchenne Trials
PremiumCompany Announcements
Percheron Therapeutics Advances in Duchenne Therapy TrialsOptions Prices
Currently, No data available
---
Ownership Overview
PER FAQ
What was Percheron Therapeutics’s price range in the past 12 months?
Percheron Therapeutics lowest share price was AU$0.05 and its highest was AU$0.14 in the past 12 months.
What is Percheron Therapeutics’s market cap?
Currently, no data Available
When is Percheron Therapeutics’s upcoming earnings report date?
Percheron Therapeutics’s upcoming earnings report date is Feb 26, 2025 which is in 91 days.
How were Percheron Therapeutics’s earnings last quarter?
Percheron Therapeutics released its earnings results on Aug 29, 2024. The company reported -AU$0.008 earnings per share for the quarter, missing the consensus estimate of -AU$0.006 by -AU$0.002.
Is Percheron Therapeutics overvalued?
According to Wall Street analysts Percheron Therapeutics’s price is currently Undervalued.
Does Percheron Therapeutics pay dividends?
Percheron Therapeutics does not currently pay dividends.
What is Percheron Therapeutics’s EPS estimate?
Percheron Therapeutics’s EPS estimate is -AU$0.02.
How many shares outstanding does Percheron Therapeutics have?
Percheron Therapeutics has 1,059,937,600 shares outstanding.
What happened to Percheron Therapeutics’s price movement after its last earnings report?
Percheron Therapeutics reported an EPS of -AU$0.008 in its last earnings report, missing expectations of -AU$0.006. Following the earnings report the stock price went up 2.439%.
Which hedge fund is a major shareholder of Percheron Therapeutics?
Currently, no hedge funds are holding shares in AU:PER
---
Percheron Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.25 (248.52% Upside)
AU$0.25 (248.52% Upside)
Blogger Sentiment
Bullish
AU:PER Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $19.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.00%
12-Months-Change
Fundamentals
Return on Equity
-121.27%
Trailing 12-Months
Asset Growth
13.51%
Trailing 12-Months
Company Description
Percheron Therapeutics
Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded in November 13, 2000 and is headquartered in Toorak, Australia.
---
PER Stock 12 Month Forecast
Average Price Target
AU$0.25
▲(248.52% Upside)
Technical Analysis
Advaxis
―
Arrowhead Pharmaceuticals
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Percheron Therapeutics
―
Best Analysts Covering PER
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-22.95%
reiterated a buy rating 19 days ago
Copying Melissa Benson's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -22.95% per trade.
---